Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chien-Chung Lin

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
The Journal of Molecular Diagnostics : JMD|October 13, 2018
Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer AssessmentFang Wei, Charles M Strom, Jordan Cheng, et al.
Scientific Reports|March 9, 2023
Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsChang-Yao Chu, Chien-Yu Lin, Chien-Chung Lin, et al.
Nanoscale Research Letters|August 16, 2019
Design, Modeling, and Fabrication of High-Speed VCSEL with Data Rate up to 50 Gb/sChih-Chiang Shen, Tsung-Chi Hsu, Yen-Wei Yeh, et al.
Nanoscale Research Letters|December 23, 2018
Liquid Type Nontoxic Photoluminescent Nanomaterials for High Color Quality White-Light-Emitting DiodeChih-Hao Lin, Yung-Min Pai, Chun-Fu Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 TrialBenjamin Levy, Luis Paz-Ares, Chien-Chung Lin, et al.
The Journal of Molecular Diagnostics : JMD|June 5, 2020
Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and SalivaMichael Tu, Jordan Cheng, Yi-Lin Chen, et al.
Scientific Reports|March 1, 2022
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapyPo-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, et al.
Frontiers in Oncology|July 26, 2021
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter StudyJason C Hsu, Phung-Anh Nguyen, Yen-Tzu Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Clinical Lung Cancer|January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on OsimertinibPascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
The Journal of Molecular Diagnostics : JMD|October 13, 2018
Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer AssessmentFang Wei, Charles M Strom, Jordan Cheng, et al.
Scientific Reports|March 9, 2023
Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsChang-Yao Chu, Chien-Yu Lin, Chien-Chung Lin, et al.
Nanoscale Research Letters|August 16, 2019
Design, Modeling, and Fabrication of High-Speed VCSEL with Data Rate up to 50 Gb/sChih-Chiang Shen, Tsung-Chi Hsu, Yen-Wei Yeh, et al.
Nanoscale Research Letters|December 23, 2018
Liquid Type Nontoxic Photoluminescent Nanomaterials for High Color Quality White-Light-Emitting DiodeChih-Hao Lin, Yung-Min Pai, Chun-Fu Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 TrialBenjamin Levy, Luis Paz-Ares, Chien-Chung Lin, et al.
The Journal of Molecular Diagnostics : JMD|June 5, 2020
Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and SalivaMichael Tu, Jordan Cheng, Yi-Lin Chen, et al.
Scientific Reports|March 1, 2022
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapyPo-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, et al.
Frontiers in Oncology|July 26, 2021
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter StudyJason C Hsu, Phung-Anh Nguyen, Yen-Tzu Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Clinical Lung Cancer|January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on OsimertinibPascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.
Pageof 20